News Releases
Mar 14 2005
Peregrine Pharmaceuticals Announces Third Quarter Financial Results
Mar 7 2005
'Clinical Cancer Research' Article States Tarvacin(TM) Equivalent Inhibits Tumor Growth by up to 90% in Multiple Tumor Models
Mar 2 2005
Journal of Clinical Oncology Publishes Significant Anti-Tumor Activity of Tumor Necrosis Therapy for Treating Patients With Advanced Lung Cancer
Feb 17 2005
Avid Bioservices Signs Commercial Manufacturing Contract With Halozyme Therapeutics
Feb 14 2005
Peregrine Pharmaceuticals Presents Data at 7th International Symposium on Anti-Angiogenic Agents
Feb 10 2005
Prominent Scientist Joins Peregrine Pharmaceuticals' Scientific Resource Board
Feb 8 2005
Peregrine Pharmaceuticals Adds Two Prominent Virologists to Its Scientific Resource Board
Jan 27 2005
Peregrine Receives FDA Approval to Proceed With Tarvacin(TM) Phase I Study
Jan 24 2005
Peregrine Gains Access to Merck KGaA's Protein Expression Technology
Jan 21 2005
Peregrine and New Approaches to Brain Tumor Therapy (NABTT) Consortium Receive Approval for Cotara(R) Brain Cancer Protocol